BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Genetown

  VBI Vaccines Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Upsized Registered Direct Offering for Aggregate Proceeds of $71.9M

  The pricing for the underwritten public offering was for a total of 16,100,000 common shares.

  October 30, 2017

   · 

  5 min read
• Business

  Genetic Technologies Limited: Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the Quarter Ended 30 September 2017

  The Annual Report is available on the Company’s website at www.gtglabs.com

  October 30, 2017

   · 

  12 min read
• 

  Drug Development

  Daiichi Sankyo’s Tumor Drug Meets Primary Endpoint in Late-Stage Study

  Daiichi Sankyo announced that its Phase III ENLIVEN trial of pexidartinib met its primary endpoint.

  October 30, 2017

   · 

  2 min read

   · 

  Mark Terry